nejm semaglutide ckd flow trial kidney outcomes hazard ratio 0.76 2024 Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk 🚨 Journal Club: FLOW Trial – A comparison of the effects – Semaglutide in patients with overweight

The aforementioned results suggest that metformin could effectively inhibit erastin-induced ferroptosis to improve the survival of NSCs, and inhibition of AMPK phosphorylation with compound C counteracted the ferroptosis inhibitory effect of metformin

Clinical Evidence for GLP-1s in Seniors Retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, is currently in Phase 3 trials with no FDA approval yet

Rbm8a regulates neurogenesis and reduces Alzheimer's disease-associated pathology in the dentate gyrus of 5FAD mice

However, athletes considering these medications primarily for body composition changes (rather than health-related weight loss) should understand that muscle preservation requires deliberate, intensive effort

Vague or rushed conversations about this are a red flag

The most common side effects include mild nausea, occasional stomach discomfort, and changes in bowel movements